Scolr Pharma Inc (SCLR)

SCOLR Pharma, Inc., specialty pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold. The company is also developing IR Raloxifene for osteoporosis; ER Ondansetron, an anti-nausea drug; ER Phenylephrine a decongestant; and ER Niacin for cardiovascular disorders. In addition, it provides various formulation products for applications, including expectorant, analgesic, sleep aid, cough-cold, decongestant and antihistamine, hypercholesterolemia and hypertriglyceridemia, pain management, beta-blockers, Ca Channel blockers, Alzheimer’s disease, schizophrenia/bi-polar, diabetes, motion sickness, asthma, and bronchodilator. SCOLR Pharma, Inc. has a strategic alliance with Perrigo Company of South Carolina, Inc. for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Redmond, Washington. As of October 3, 2016, SCOLR Pharma, Inc. operates as a subsidiary of Probi USA, Inc.